Lung Cancer

Sometimes patients with cancer need to adjust their thinking to change how they view their disease

Question: When do cancer scans shift from disease monitoring to routine checkups? Answer: You decide.

The approval is based on data from the phase 3 CheckMate-057 trial, in which second-line Opdivo reduced the risk of death by 28 percent versus docetaxel in patients with nonsquamous NSCLC.

The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.

Carolyn Presley discusses the implications of screening on diagnosis and treatment of lung cancer.

Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.

The stage 4 lung cancer life twists and turns down a bumpy road, but it is a road that I am lucky enough to still be traveling.

To gain a patient's perspective on the Genomics of Young Lung Cancer Study and the importance of genomic testing, we spoke with Corey Wood, a 23-year-old trial participant and lung cancer survivor.

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.

This is how my family and I were thrown into the cancer world.

Marianne Davies, from Smilow Cancer Hospital, Yale School of Nursing, provides an overview of immunotherapy-related side effects that patient with lung cancer may experience.

At an 18-month analysis, the overall survival rate with the PD-1 inhibitor was 28 percent versus 13 percent with docetaxel in previously treated patients with squamous NSCLC.

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

I have a rare mutation causing my cancer. Are there any others with ROS1 out there?

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of MET exon 14 skipping mutations in lung cancer.

The addition of Avastin (bevacizumab) to chemotherapy after initial therapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

My dad was diagnosed with Stage 4 lung cancer in February of 2014. His diagnosis included the BRAF mutation, which is still in the process of being researched for successful treatments.

Kim Statham Ringen, DVM DACVIM (Oncology), a CURE contributor who is currently surviving stage 4 non-small cell lung cancer, discusses the importance of meeting other cancer survivors.

Kim Statham Ringen, DVM DACVIM (Oncology), a CURE contributor who is currently surviving stage 4 non-small cell lung cancer, discusses the stigma of lung cancer.

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies, according to a preliminary analysis of data from an ongoing study.

Pneumonitis, a lung inflammation, often appears months after the cancer treatment that sparked it.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with lung cancer with brain metastases.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

E-cigarettes, championed by some as a smoking-cessation tool, may actually decrease the likelihood of quitting smoking, according to a recent population-based study of 1,000 smokers published in The American Journal of Public Health.

It's incredible how much personality was squeezed into my mother's 4'10" frame. She was a spitfire. A burst of energy, starting friendly conversations with anyone and everyone she met.

After nearly four years of cancer treatment, I thought I'd experienced all possible types of scanxiety. I was wrong.

The FDA has granted a breakthrough therapy designation to the immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with non-small cell lung cancer.

Preliminary data from a phase 2 trial demonstrates that a combination of the PARP inhibitor veliparib and chemotherapy benefits patients with squamous cell non-small cell lung cancer.